Ovarian Function Suppression in Premenopausal Women With Breast Cancer
Dario Trapani, Medical oncologist at the European Institute of Oncology (IEO), shared a post by Salvador Santiesteban, Medical Oncologist from the National Institute of Medical Sciences and Nutrition on X, adding:
“Inconsistent trial-based definitions, ‘confusion’ with amenorrhea and historical reliance on surrogate metrics vs pharmacodynamics has resulted in complexity where gonadal suppression in breast cancer is a clinical consideration; it’s biochemical in prostate cancer.”
Quoting Salvador Santiesteban‘s post:
“Clinical Management of Ovarian Function Suppression in Premenopausal Women With Breast Cancer: A Survey of Members of ASCO | JCO BCSM.”
Authors: Catherine M. Kelly, et al.
Dario Trapani is a medical oncologist at the European Institute of Oncology (IEO) and a researcher in the Department of Oncology and Hemato-oncology at the University of Milan. He previously served as a Postdoctoral Researcher at the Dana-Farber Cancer Institute, and is focused on population health research.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023